The protease medicines company
Learn more
Harnessing the catalytic power of proteases
Developing protease therapeutics to address unmet medical needs in disorders of the complement system
Catalyst Biosciences Sells Complement Portfolio for $60 Million
Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results
Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate Update
More news
